Microdosing Tirzepatide: What the Dose Response Data Does and Does Not Say

Microdosing tirzepatide means running it below the 2.5 mg weekly starting dose, usually somewhere between 0.5 mg and 1.25 mg. It is not a protocol anyone has tested. Every published efficacy figure for this molecule comes from the 5, 10 and 15 mg arms of the SURMOUNT trials, and the lowest dose ever taken into a weight loss trial is the 2.5 mg step that exists purely to let people tolerate the climb to a treatment dose.

That does not make microdosing irrational. It makes it extrapolation, and the useful thing is to be clear about which parts are arithmetic, which parts are pharmacology, and which parts are guesswork. This page covers all three, plus the reconstitution maths that small doses actually turn on. For the standard schedule see the tirzepatide dosage guide. This is research use information, not medical advice.

What People Mean by Microdosing

The term has no formal definition here, and it gets used for at least three different things.

• Sub threshold starting. Beginning at 0.5 mg or 1 mg weekly instead of 2.5 mg, then climbing in smaller increments. The intent is to reach a normal dose eventually, just more gently.
• Sub threshold maintenance. Losing weight on a conventional dose, then dropping to 1 mg or 1.25 mg weekly to hold the result on less drug.
• Permanent low dose use. Running 0.5 mg to 1.25 mg indefinitely without ever intending to escalate, usually for cost reasons or because a small appetite effect is all that was wanted.

These are three different questions with three different evidence positions, and lumping them together is how most of the online discussion goes wrong. The first is a titration variation. The second has a mechanistic argument behind it. The third is the one with essentially nothing to support it.

Why People Do It

Three motives account for nearly all of it, and they are not equally sound.

Side effects. Tirzepatide's gastrointestinal effects are dose related and adapt with exposure, which is why the approved schedule steps up over months rather than starting at target. Somebody who cannot get past 2.5 mg has a real problem, and approaching it from below is a coherent response. The profile is covered in tirzepatide side effects.

Cost. A lower dose stretches a vial further, and for many people this is the actual reason regardless of what else is said. The tirzepatide cost page covers how the per milligram maths works out across supply routes. The uncomfortable part is that cost driven dose selection is dose selection by budget rather than by response, and a dose that produces nothing is not cheap, it is wasted.

Maintenance. After a weight loss phase, the question becomes how little drug is needed to hold the result rather than produce it. This is the most defensible use of the three, because holding a reduced weight plausibly demands less appetite suppression than producing the reduction did. It remains an inference. No maintenance dose finding trial has been run below 2.5 mg.

What the Trial Data Actually Covers

SURMOUNT-1 randomised adults with obesity, or overweight with a weight related condition and without diabetes, to tirzepatide 5, 10 or 15 mg weekly or placebo for 72 weeks. The results were dose ordered.

Two readings of that table are both correct and point in opposite directions. The curve flattens: going from 10 mg to 15 mg buys 1.4 percentage points, while the first 5 mg buys almost twelve. If most of the effect arrives early in the dose range, then extending the curve downward makes a low dose look more interesting than a naive linear reading would suggest.

The other reading is that the lowest point measured is 5 mg, and a curve says nothing about the region past its endpoint. Dose response relationships in receptor pharmacology are sigmoid, not linear, and the bottom of a sigmoid is flat. There is a dose below which a GLP-1 and GIP receptor agonist produces no meaningful appetite effect at all. Nobody has published where that threshold sits, and 0.5 mg weekly could plausibly be on either side of it.

The Reconstitution Maths

Small doses are where arithmetic errors become expensive, because the volumes involved get close to the resolution of the syringe. The three steps do not change. Concentration is vial milligrams divided by millilitres of bacteriostatic water. Volume per dose is dose divided by concentration. Units are that volume multiplied by 100 on a U-100 barrel.

The top row is the trap. At 10 mg/mL a 0.5 mg dose is five marks on a U-100 barrel, and a one mark misread is a twenty percent dose error. Diluting further moves the same dose into a range where the same absolute misread costs far less proportionally, which is the single most useful adjustment anyone microdosing can make. The constraint at the other end is that more water means more volume injected and a vial that has to stay stable for longer, so a 10 mg vial in 3 mL to 4 mL is the usual compromise. Any combination can be checked against the tirzepatide dosage calculator, and general technique is in how to reconstitute peptides.

Two further points on small volumes. Insulin syringes are calibrated for accuracy across their working range, not at the very bottom of the barrel, so a 0.05 mL draw carries more relative error than a 0.4 mL draw. And a vial diluted to 4 mL and drawn at 0.2 mL per week lasts about twenty weeks, which is a long time for a reconstituted peptide to sit in a fridge with repeated stopper punctures.

The Compounded Vial Problem

Every number above assumes the vial contains 10 mg of tirzepatide. That assumption does more work in a microdosing protocol than in a standard one, and it is the weakest link in the chain.

Lyophilised peptide powder is typically not 100 percent peptide by mass, and content varies between suppliers and between batches. On a 10 mg weekly dose, a vial running fifteen percent under label is a difference nobody would detect against normal week to week variation. On a 0.5 mg dose sitting near a threshold, the same fifteen percent could be the difference between an effect and nothing at all, and the person would reasonably conclude that microdosing does not work when what actually happened was a supply problem. The category distinctions and what testing exists are set out in compounded tirzepatide.

There is also a measurement problem in the other direction. Anyone running a dose nobody has trialled is running an experiment with one participant, no control, no blinding and an outcome measure that moves several pounds on water weight alone. That design cannot distinguish a small real effect from no effect, which means confident claims in either direction about sub threshold doses are not supported by the thing generating them.

An Honest Position

Approaching 2.5 mg from below because that step is intolerable is reasonable, has a clear mechanistic rationale, and costs little to try. Dropping to a low dose for maintenance after a successful weight loss phase is a defensible inference that the maintenance requirement is lower than the induction requirement, and it is the version of microdosing most likely to hold up if it is ever studied.

Running 0.5 mg indefinitely as a cheaper substitute for a treatment dose is a different proposition. It may be below the threshold where the receptors do anything useful, it costs months to find out, and the weight regain pattern after stopping a GLP-1 based drug does not reward months spent on a dose that was never doing much. If the constraint is cost, comparing supply routes in the cost breakdown or considering the single agonist covered in semaglutide versus tirzepatide is a more honest response than quietly hoping a tenth of a trial dose behaves like a fifth of one.

Key Takeaways

• Microdosing here means below the 2.5 mg starting dose, typically 0.5 mg to 1.25 mg weekly
• SURMOUNT-1 studied 5, 10 and 15 mg, giving 15.0, 19.5 and 20.9 percent mean weight loss at 72 weeks against 3.1 percent on placebo
• No trial has tested any dose below 2.5 mg, so every sub threshold protocol is extrapolation
• The dose response curve flattens at the top but nobody has published where it flattens at the bottom
• Dilute a 10 mg vial to 3 mL or 4 mL so a small dose is not five marks on a barrel
• Under label vial content matters far more at 0.5 mg than at 10 mg
• Maintenance microdosing is the most defensible version, permanent low dose substitution the least

Frequently Asked Questions

What is a microdose of tirzepatide?

There is no formal definition, but in practice it means any weekly dose below the 2.5 mg starting step, most commonly 0.5 mg to 1.25 mg. For reference, the doses studied in the SURMOUNT weight loss trials were 5, 10 and 15 mg weekly, and 2.5 mg exists only as a tolerability step on the way up rather than as a tested treatment dose.

Does microdosing tirzepatide work for weight loss?

Nobody knows, because no trial has measured any dose below 2.5 mg. SURMOUNT-1 reported 15.0 percent mean weight loss on 5 mg, 19.5 percent on 10 mg and 20.9 percent on 15 mg at 72 weeks, against 3.1 percent on placebo. The curve flattens at the top, which some read as evidence that most of the effect arrives early, but receptor dose response curves also flatten at the bottom and nobody has published where that lower threshold sits.

How do you measure a 0.5 mg dose of tirzepatide?

By diluting enough that the dose is not a handful of marks on the syringe. A 10 mg vial in 1 mL gives 10 mg/mL, so 0.5 mg is only 5 units on a U-100 barrel and a one mark misread is a twenty percent error. The same vial in 4 mL gives 2.5 mg/mL, putting 0.5 mg at 20 units where the same absolute error costs far less. A 10 mg vial in 3 mL to 4 mL is the usual compromise between accuracy and how long the vial then has to stay stable.

Is microdosing tirzepatide safer than a full dose?

Gastrointestinal side effects are dose related, so a lower dose generally produces fewer of them, and starting below 2.5 mg is a coherent response to being unable to tolerate the standard first step. Safer is not the same as better, though. A dose too low to do anything carries a different cost, which is months spent on a protocol that was never going to work, and the risks associated with unverified compounded material do not scale down with the dose.

Can you microdose tirzepatide to maintain weight loss?

This is the most defensible version of the idea, because holding a reduced weight plausibly needs less appetite suppression than producing the reduction did. It is still an inference rather than a finding. No maintenance dose finding trial has been run below 2.5 mg, so anyone stepping down is testing it on themselves, and weight regain after reducing or stopping a GLP-1 based drug is well documented enough to be worth watching for.